Amylin, Alkermes up after meta-analysis

Shares of Amylin (NASDAQ:AMLN) and Alkermes (NASDAQ:ALKS) gained on Thursday after a meta-analysis of 3,900 patients from 12 completed trials ranging from 12-52 weeks showed that twice-daily Byetta ex...